Specify a stock or a cryptocurrency in the search bar to get a summary
Next Science Ltd
NXSCFNext Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia. Address: Australia Square, Sydney, NSW, Australia, 2000
Analytics
WallStreet Target Price
0.56 AUDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures NXSCF
Dividend Analytics NXSCF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NXSCF
Stock Valuation NXSCF
Financials NXSCF
Results | 2019 | Dynamics |